Abstract
Background Two RCTs demonstrated efficacy and safety of IV alteplase for patients with acute ischemic stroke (AIS) who awaken with symptoms or with last known well (LKW) more than 4.5 hours prior to arrival. However, real world experience using CT perfusion (CTP) or DWI-MRI for patient selection in the U.S. is limited. We developed the Tufts Late Presenter Thrombolysis (LPT) protocol to offer alteplase to patients with wakeup stroke, known LKW more than 4.5 hours, or unknown LKW likely more than 4.5 hours and less than 24 hours, using CTP or DWI-MRI to aid patient selection.
Methods We reviewed ED stroke codes from our Comprehensive Stroke Center between 1/1/20-12/31/22 to identify patients treated with alteplase. Data were collected on demographics, comorbidities, LKW-to-treatment time (LTT), imaging modality, imaging findings, NIHSS, vessel occlusions, endovascular therapy (EVT), symptomatic ICH, and 90 days mRS. Outcomes for comparative analyses included process times (door to needle, door to CT) and clinical outcomes (90 day mRS, symptomatic ICH).
Results Forty-three of 118 patients (36%) presenting with AIS and treated with thrombolysis were treated between 4.5-24 hours after LKW. Patients treated in the 4.5 hour window and the later window had similar demographics, comorbidities, NIHSS, and EVT rates. CTP was used in the majority of LPT cases. The median penumbra was 45.04 mL (11.55-83.21), and the median core infarct was 5.92 mL (1.89-16.7). Symptomatic intracranial hemorrhage occurred in one LPT case (2.3%). Favorable mRS (0-1) was achieved by 36% of LPT patients with documented 90 day mRS.
Conclusions A pragmatic protocol offering thrombolysis to late presenters may be safe and achieve favorable outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A (not a trial)
Funding Statement
None.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Tufts Medical Center IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data from this study is available from the corresponding author upon reasonable request.
